Mylan 4th-qtr profits beat expectations, but not sales

US generic drugs major Mylan (Nasdaq: MYL) yesterday posted financial results for the three months and year ended December 31, 2011 that were mixed in terms of analysts’ consensus expectations.

Adjusted diluted earnings per share were $0.53 for the fourth quarter, an increase of 18%; compared with estimates of $0.50 from analysts polled by Thomson Reuters. Adjusted diluted EPS of $2.04 for the year ended December 31, 2011 compared to $1.61 for the prior year, an increase of 27%;

Total revenues of $1.53 billion for the fourth quarter were up 7%. Revenues for the three months were negatively impacted by foreign currency translation, the impact of which was 1% (around $18 million) compared to the same prior year period, and 2.5% (about $39 million) on a sequential quarter basis. Total revenues for the full year 2011came in at $6.13 billion, a rise of 12%.